Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (

IGF1R The insulin-like growth factor 1 (IGF-1) receptor is a protein found on the surface of human cells. It is a transmembrane receptor that is activated by a hormone called insulin-like growth factor 1 (IGF-1) and by a related hormone called IGF-2. ...

), designed for the treatment of cancers. Ganitumab was developed by

Amgen Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical Corporation, company headquartered in Thousand Oaks, California. As one of the world's largest independent biotechnology companies, Amgen has a ...

. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.

References

Drugs developed by Amgen Abandoned drugs {{antineoplastic-drug-stub